At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Mepolizumab +2 moredrug
Likely dose
Mepolizumab 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis
In Brief
A Phase 2 clinical trial evaluating Mepolizumab, Placebo, and 1 other intervention for Nasal Polyps. Completed, enrolled 109 participants across 6 sites in 3 countries.
Detailed Summary
A two-part, randomised, double-blind, placebo controlled, multi-centre study to investigate the use of mepolizumab (SB-240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyps
CountriesBelgium, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedMay 2011
Primary CompletionDec 2014
TodayJul 2026
First PostedMay 30, 2011
Enrollment StartMay 12, 2009
Primary CompletionDec 5, 2014
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.1 years ago
Interventions
Mepolizumabdrug
750 mg of mepolizumab by IV infusion
Placebodrug
Placebo by IV infusion
Run In Medicationdrug
subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).